Investing, Biotechnology, Venture Capital, Science, Immune System.
prominent hypothesis in IL-2 engineering has been to develop mutants with biased affinity for the dimeric complex to spare immunosuppressive Tregs, a strategy referred to as “not alpha” IL-2. However, the authors argue that even though “not alpha” candidates ablate CD25 binding, they will still